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THE HARVEY LECTURES, SERIES 95

LEPTIN AND THE REGULATION OF
BODYWEIGHT
JEFFREY M. FRIEDMAN
Laboratory ofMolecular Genetics, Howard Hughes Medical Institute,
The Rockefeller University, New York, New York
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I. INTRODUCTION

he assimilation, storage, and utilization of nutrient energy constitute
a complex homeostatic system essential for life. In vertebrates, and es
pecially among land-dwelling mammalian species, the ability to store suf
ficient quantities of energy-dense triglyceride in adipose tissue permits
survival during the frequent periods of food deprivation often encoun
tered during evolution. However, the presence of excess adipose tissue is
maladaptive and renders obese organisms more susceptible to predation
and less effective at hunting. In addition, the accumulation of excess adi
pose tissue in humans increases the risk for developing hypertension, dia
betes, and cardiovascular disease, all of which are major causes of
morbidity. In order to regulate fuel stores and energy balance at an op
timum level, a complex physiologic system has evolved.
A number of lines of evidence support the hypothesis that body weight
is regulated by a robust physiologic system. Twin studies, analyses of fa
milial aggregation, adoption studies, and studies of animal models of obe
sity all indicate that obesity is to a significant extent the result of genetic
factors [1-3]. Moreover, there is abundant evidence that weight is ex
tremely stable in lean and obese individuals [4]. This is despite the fact
that a large proportion of the population actively practices some form of
weight control. Still, dieting is not generally successful for long-term
maintenance of a reduced body weight and the majority of reduced obese·
individuals eventually regain the lost weight [5].
The relative stability of weight among most individuals has suggested
that energy balan�e in mammals is controlled by a feedback loop that
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maintains constancy of total body energy stores. This system is composed
of three components: afferent signals that report nutritional information,
a controller in the hypothalamus, and efferent signals that coordinately
regulate food intake and metabolism [6]. Thus it has been suggested that
signals that report nutritional state are sensed by the brain, specifically the
hypothalamus, which in turn modulates food intake and energy expendi
ture [7-9). However, the identification of these signals proved difficult
and, indeed, for many decades their existence was widely questioned. In
recent years, several of the key components of the system regulating body
weight have been identified, in particular, leptin and the leptin receptor
[10). These genes have human homologues and their functions are con
served among mammalian species.
II. AFFERENT SIGNALS

In the 1970s, a critical clue regarding the identity of a key nutritional
signal was suggested by studies of mutant obese (obi ob) and diabetic
(db/db) mice. Recessive mutations in the mouse ob and db genes result in
obesity and diabetes in a syndrome resembling morbid human obesity [3,
11]. Affected ob/ob and db/db mice have identical phenotypes, each mu
tant weighing three times that of normal mice with a fivefold increase in
body fat content. Data from cross-circulation (parabiosis) experiments
suggested that the ob gene encoded (or was responsible for the generation
of ) a circulating factor that regulated nutritional state and that the db gene
encoded the receptor for this factor [3].
The successful cloning and characterization of the ob gene in 1994 has
confirmed that it encodes a novel adipocyte-derived hormone. As the wild
type ob gene is required to prevent obesity, its protein product was named
"leptin" from the Greek word leptos, meaning thin. Further studies of leptin
have led to the conclusion that body fat content is regulated by a negative
feedback loop centered in the hypothalamus and elsewhere [12, 13) (Fig.
1). The data further suggest that weight is regulated by a set point mecha
nism and that weight is set at different levels among different individuals.
When at the set point, a state of energy balance in which food intake equals
energy expenditure is maintained. Increasing adipose tissue mass leads to
an increase in leptin level. This in turn induces a state of negative energy
balance until weight returns to the set point. A decreased adipose tissue
mass is associated with a decrease in leptin level, which in turn induces a
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state of positive energy balance. This system thus acts to maintain adipose
tissue mass within a relatively narrow range. In addition, this system links
changes in nutritional state to other physiologic systems (see below).
Leptin circulates as a 16-kDa protein in mouse and human plasma but
is undetectable in plasma from C57BL/6J ob/ob mice [14]. Leptin is not
modified post-translationally as the molecular mass of the native protein
is identical to that predicted by the primary sequence (without the signal
sequence) [15]. The plasma levels of leptin is highly correlated with adi
pose tissue mass and falls in both humans and mice after weight loss [16].

Controller

Leptin

Outputs:

Food consumption,
Energy Expenditure,
Metabolism, Other

Fig. 1. Leptin and the regulation ofadipose tissue mass. The cloning ofthe ob gene and
the characterization ofleptin has suggested that body fat content is under homeostatic con
trol. The available data suggest that leptin is the afferent signal in a negative feedback loop
regulating adipose tissue mass. The level ofleptin is positively correlated with differences in
body fat. Increasing leptin levels result in negative energy balance (energy expenditure <
food intake) whereas decreasing levels lead to positive energy balance (food intake > energy
expenditure). These effects maintain constancy of fat cell mass. The available data also sug
gest that the hypothalamus is an important site ofleptin action.
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The levels of protein are increased in several genetic and environmentally
induced forms of rodent obesity and in obese humans [13, 16-18].
Administration of leptin either by injection or as a constant subcuta
neous infusion results in a dose-dependent decrease in body weight at in
cremental increases of plasma leptin levels within the physiologic range
[19-24]. The dramatic effect of leptin vs. saline treatment of ob mice is
shown (Fig. 2). The potency of leptin is much higher when delivered as a
constant infusion vs. bolus injections. This indicates that the mode of de
livery may ultimately be a critical determinant of leptin's utility as a ther
apeutic agent. In both ob/ob and wild-type mice, leptin induced weight
loss is restricted to adipose tissue with sparing oflean body mass [14].
In aggregate, these data establish leptin's role as an afferent signal in a
feedback loop modulating the size of adipose tissue mass. However,

Fig. 2. Boch of these mice have a defect in the obese (ob) gene. This mutation usually re
sults in a marked increase in the amount of fat. Administration of the protein encoded by
the ob gene, called leptin, reduced the body weight of the ob mice. After 4.5 weeks, the ob
mouse on the left, which did not receive lepcin, weighed approximately 67 g, whereas the
mouse on the right, who received daily injections of lepcin, weighed 35 g. Normal mice
weigh approximately 24 g, a weight equivalent co chat of an orange. Daily injections of
leptin co ob mice reduced body weight via effects on food intake and energy expenditure,
meaning the treated animals ace less and also burned more calories.
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leptin is not the only afferent signal that regulates food intake and body
weight. The systems that control feeding behavior and energy balance
seem to be comprised of a short-term and long-term system. The short
term system regulates meal pattern and feeding throughout the day. Pre
vious work has indicated that changes in plasma glucose concentration,
body temperature, plasma amino acids, cholecystokinin, and other hor
mones can all modulate meal patterns [25, 26]. The long-term system
balances food intake and energy expenditure and thus plays a dominant
role in ultimately regulating the size of the body's energy stores. Leptin
appears to function largely within the long-term system and influences
the quantity of food consumed relative to the amount of energy that is
expended. Leptin levels do not increase significantly after a meal and it
does not, by itself, lead to the termination of a meal [16, 18]. These re
sults suggest that leptin is not a classic satiety factor. However, leptin and
the other components of the long-term system are likely to interact ex
tensively with the components of the short-term system by modulating
the amount of food that is consumed during a meal and/or the likelihood
that an organism will miss a meal.
III. REGULATION OF LEPTIN PRODUCTION
The physiologic importance of quantitative changes in leptin concen
tration suggests that regulation of the ob gene is an important control
point. The level of ob gene expression per cell is highly correlated with the
lipid content and the corresponding size of individual adipocytes [13].
Previous studies have suggested that differences in fat cell size can have an
important impact on the weight of an organism [27]. The signal trans
duction system by which fat cells sense their lipid content (possibly size)
and in turn adjust the level of ob expression is unknown. Extrinsic factors
also modulate the expression of leptin. Leptin levels increase -30% at
night and, based on sampling of levels at 5-minute intervals, also seem to
oscillate each hour [18, 28]. Although feeding does not seem to increase
leptin expression, an extended fast acutely decreases plasma leptin con
centration [16]. Other hormones also modulate ob gene expression
including insulin, glucocorticoids, tumor nerosis factor (TNF), and inter
Leukin-1 (IL-1) [29-33]. The ob promoter seems to be responsive to sev
eral transcription factors including cEBP and PPARy [31, 34-36]. It is
not known which other factors regulate the expression of ob RNA, nor is
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it known whether leptin is released from adipocytes from storage vesicles
or via the constitutive pathway of protein secretion.
IV. A BROADER ROLE FOR LEPTIN

Leptin-deficient (ob/ob) mice manifest myriad endocrine and metabolic
abnormalities [3]. Many of these derangements, which include decreased
body temperature, hyperphagia, decreased energy expenditure (including
activity), and infertility are also observed in starved animals. This has sug
gested that in the absence of leptin, ob/ob mice exist in a state of perceived
starvation and thus exhibit a constellation of signs that are characteristic of
the starved state. Indeed, in circumstances where food is readily available,
this biologic response would be expected to lead to the massive obesity ev
ident in ob/ob mice. As predicted by such a model, replacement of leptin
was found to correct all of the aforementioned abnormalities of mutant
ob/ob mice [14, 21, 37].
The possibility that falling plasma leptin levels signal nutrient deprivation
is further suggested by the observation that exogenous leptin attenuates the
neuroendocrine responses to food restriction [38]. Fasted wild-type mice
receiving leptin continue to ovulate whereas fasted controls given PBS expe
rience an ovulatory delay of several days. Leptin treatment blunts the
changes in circulating thyroid hormone and corticosterone levels that are
normally associated with food deprivation [38]. Starvation is also associated
with decreased immune function and leptin corrects these abnormalities
[39]. Leptin stimulates proliferation of CD4 + T cells and increases produc
tion of cytokines by T-helper-1 cells [39]. These results indicate that leptin
may also be a key link between nutritional state and the immune system.
Leptin is also important in regulating the onset of puberty. Extremely
thin women often stop ovulating, and abnormally thin adolescent women
enter puberty later than their heavier counterparts. These observations
have suggested that reproductive capability in woman is suppressed in the
absence of adequate nutritional stores. These findings have further sug
gested that fat tissue may produce a signal that regulates reproduction
[40]. This factor may be leptin. Treatment of prepubertal female mice
with leptin accelerates the maturation of the female reproductive tract and
leads to an earlier onset of the oestrous cycle and reproductive capacity
[41, 42]. In humans, a surge in plasma leptin concentration is seen in pre
pubertal females [43]. The evidence suggests that sufficient levels of leptin
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are necessary but not sufficient for the onset of puberty. These studies sug
gest that leptin modulates reproductive function and provides a direct link
between reproduction and the nutritional status of an animal.
These observations led to speculation that leptin's primary physiological
role is to signal nutritional status during periods of food deprivation [26,
44]. However, leptin's physiologic role in preventing weight gain has re
cently received significant experimental support. As mentioned, lean mice
given chronic infusions of leptin lose adipose mass in a dose-dependent
fashion at leptin levels within the physiologic range [19, 45]. These data
indicate that dynamic changes in plasma leptin concentration act to resist
weight change in either direction.
V THE LEPTIN RECEPTOR AND LEPTIN'S SITES OF ACTION
The leptin receptor is a member of the cytokine family of receptors.
These receptors have a single transmembrane domain and are generally ex
pressed as monomers or dimers on the cell surface. Ligand binding induces
dimerization and/or activation of the receptor and activates signal trans
duction. Ob-R is predicted to have two separate leptin binding regions and
binds leptin with nanomolar affinity [46]. The stoichiometry of binding is
not yet known, although the related granulocyte colony-stimulating factor
(G-CSF) receptor also has two binding domains and binds to G-CSF with
a ligand:receptor ratio of 2:2 [47].
There are several different forms of the leptin receptor, one expressed at
a high level in choroid plexus and other tissues, known as Ob-Ra, and an
other expressed in hypothalamus and elsewhere, known as Ob-Rb. Ob-Rb
(also referred to as Ob-R-L) has a long cytoplasmic region with several
motifs required for signal transduction [ 46, 48-51]. The other splice vari
ants, ObRc-e, have also been identified. Ob-Ra is missing motifs generally
required for signal transduction by this class of receptors.
Mutations that disrupt the leptin receptor have been identified in each
of the available alleles of genetically obese db mice as well as fa rats, the rat
homologue of db [52]. In the C57BL/Ks db/db mutation, the Ob-Rb
transcript is specifically mutant whereas the other splice variants are
normal J48, 53]. This db mutation is the result of abnormal splicing
leading to the insertion of a 106-bp fragment including a premature stop
codin into the 3' end of Ob-I�.b RNA. The insertion is derived from the
Ob-Ra 3' end and, as a consequence, the Ob-Ra protein is expressed in
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place of Ob-Rb in this mouse strain. The phenotype of these C57BLKs
db/db mice is indistinguishable from that of ob mice. As ObRb is the only
form of the receptor that is deranged in these mutant mice, these data es
tablish that Ob-Rb is absolutely necessary for leptin to exert its weight re
ducing effects. Ob-Rb is normally expressed at a high level in the
hypothalamus and other brain regions, T cells, and vascular endothelial
cells and at a lower level in many other tissues [39, 48, 49, 54, 55].
The high level of Ob-Rb in hypothalamus suggests that this brain region
is an important site of leptin action [48, 49]. In situ hybridization has iden
tified the arcuate, DMH, paraventricular nucleus (PVN), VMH, and LH
hypothalamic nuclei as the principal sites of Ob-Rb expression [52, 56,
57]. These hypothalamic nuclei have all been shown to play a role in regu
lating food intake and body weight [8]. Leptin is also expressed in other
brain regions including the cortex, thalamus, and the limbic lobe [55]. Fur
ther evidence in support of a hypothalamic site of action for leptin was sug
gested by the observation that leptin induces a dose-dependent activation
of the STAT3 transcription factor in the hypothalamus of mice within 15
minutes of a single intraperitional injection [58]. STAT3 activation was not
observed in any other tissues. Leptin also increases the level of expression of
fos, a STAT3 target, and several other genes in the hypothalamus [59].
Defects in leptin signal transduction may also be important in the de
velopment of leptin resistance. Studies of the function of the lepcin re
ceptor in vitro have confirmed chat Ob-Rb is capable of activating signal
transduction [49-51, 60]. The introduction of mutations into Ob-Rb
have identified several sequences in the carboxy terminus chat are required
for activation of different signal transduction pathways [50, 51]. These
studies have indicated chat activation of the leptin receptor is dependent
on phosphorylation of the JAK2 kinase after ligand binding co an Ob-Rb
homodimeL Leptin also leads to the tyrosine phosphorylation of the SHP2, a phosphotyrosine phosphatase, which in turn decreases both the state
ofJAK-2 phosphorylation and transcription of a leptin-inducible reporter
gene [61, 62]. Thus, SHP-2 may play a role in shutting off the lepcin
signal transduction pathway. SOCS-3, a suppressor of JAK signaling, has
also been implicated in lepcin signal transduction and may also play a role
in down-regulating the response co lepcin [63]. Ochp components of the
lepcin signal transduction pathway have not yet been identified.
The synaptic transmission of neurons from the arcuate nucleus is altered
by lepcin [64]. Lepcin leads to the hyperpolarization of some hypothalamic
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neurons and replicates the effect ofglucose on these cells [65]. This effect is
dependent on a KAJ"P channel as tolbutamide inhibits the effect [65]. These
electrophysiologic effects are rapid aO:d are unlikely to require new tran
scription via activation of STAT or other proteins. The components of the
leptin signal transduction that alter electrical activity in neurons are not yet
known and their identification could provide new therapeutic targets.
The importance ofthe central nervous system (CNS) as a site ofleptin ac
tion has also been assessed in comparisons between peripherally and centrally
administered leptin. A single injection ofleptin ICV reduces food intake at
doses that have no effect when delivered peripherally [19, 22, 23, 66].
Chronic infusion ofleptin ICV at a dose of3 ng/hr results in total depletion
of body adipose stores whereas peripheral administration requires doses
greater than 500 ng/hr to achieve the same effect [19]. The effect of a 3 ng/hr
ICV dose seems to be at the peak of the dose response curve as higher doses
(50 and 500 ng/hr) have an identical effect. To date, all of the weight-re
ducing and anorectic effects ofperipheral leptin are reproduced by low-dose
leptin infused into the III ventricle as are the effects ofleptin on glucose and
fat metabolism [19, 67, unpublished observation]. These data establish leptin
as the most potent weight-reducing peptide known when delivered into the
CSF and suggest that the CNS is a major site ofleptin action.
Leptin also acts on peripheral cell types and has direct mitogenic effects
on CD4 + human T cells [39] (Fig. 3). Leptin has direct effects on endothe
lial cells directly and increases angiogenesis, although high doses are required
[54]. Leptin modulates pancreatic cell function in vivo and has direct effects
on other cell types in vitro [68]. The leptin receptor is widely expressed, al
though the Ob-Ra (short) form of the receptor predominates in many of
these tissues [48, 49, 57]. Although the potency of i.c.v. leptin indicates that
direct peripheral effects are not absolutely required for weight loss, the full
spectrum ofits actions is not known. It is thus possible that leptin acts on a
variety of tissues and thus functions in other physiological systems.
The importance of Ob-Ra expression or the other forms of the receptor
in a particular tissue is not clear. Ob-Ra could function in the transport of
leptin across the blood brain barrier or in clearance of the peptide from
the CSF [46, 69]. At present, however, the mechanism of leptin transport
into the CNS has not been elucidated. Ob-Ra may also serve functions·
dishnct from Ob-Rb and could even form complexes with other cell sur
face proteins that in turn respond to leptin. A soluble form of the leptin
receptor, Ob-Re, has also been identified in mouse and human plasma
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Fig. 3. Leptin is secreted from adipocytes either as a 16 kDa protein or bound to a sol
uble form of its receptor. The level ofleptin is positively correlated with differences in body
fat. Increasing leptin levels result in negative energy balance (energy expenditure < food in
take) whereas decreasing levels lead to positive energy balance (food intake > energy expen
diture). Leptin acts predominately on the hypothalamus. Extensive connections exist
between the hypothalamus and other brain regions. Leptin acts centrally to decrease food in
take and modulate glucose and fat metabolism. Peripheral effects on T cells, pancreatic islets,
and other tissues have also been demonstrated. CVO, circumventricular organ.

[ 62, 70]. The function of Ob-Re is unknown and experiments that test
the effects of recombinant Ob-Re are necessary. In most cases, such as
with the growth hormone and interferon, soluble receptors chelate the
ligand and have inhibitory effects but in the case of CNTF, the soluble re
ceptor can activate signal transduction [71-73].
VI. THE NEURAL CIRCUIT REGULATING WEIGHT

The available data suggest that the concentration of leptin is sensed by
groups of neurons in the hypothalamus and other brain regions. During
starvation, leptin levels fall thus activating a behavioral, hormonal, and
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metabolic response that is adaptive when food is unavailable. Weight gain
increases plasma leptin concentration and elicits a different response
leading to a state ofnegative energy balance. It is as yet unclear whether
the same (or different) neurons respond to increasing vs. decreasing leptin
levels. In addition, the spectrum ofleptin's effects is likely to be complex
as recent studies have indicated that different thresholds exist for several of
leptin's effects [74].
As mentioned, various nuclei in the hypothalamus have been implicated
in the control offood intake and their role with respect to leptin action has
recently been examined. Leptin receptors have been localized to several of
these hypothalamic nuclei including the arcuate, VMH, LH, DMH, and
PVN [8, 52, 56, 57]. The LH and VMH project both within and outside
the hypothalamus and modulate activity ofthe parasympathetic and sym
pathetic nervous system, respectively [75]. The DMH also has inputs to
the parasympathetic nervous system and has been implicated in integrating
information among the VMH, LH, and PVN. The PVN controls secretion
ofpeptides from both the posterior and anterior pituitary and projects to
nuclei with sympathetic or parasympathetic efferents [75]. The PVN also
projects to numerous sites outside ofthe hypothalamus including higher
centers known to modulate motivational behaviors.
Each of these hypothalamic nuclei express one or more neuropeptides
and neurotransmitters that regulate food intake and/or body weight (Table
I). Genetic evidence has implicated several ofthese neuropeptides as playing
a role in the response to leptin and other nutritional signals. The data are
consistent with the possibility that neuropeptide Y (NPY) and melanin
concentrating hormone (MCH) play a role in the response to absent (and
possibly low) leptin levels, whereas centrally expressed amelanocyte stimu
lating hormone (aMSH), its MC-4 receptor, and the Agouti related tran
script (ART also known as AGRP) play a role in the response to an increased
plasma leptin concentration (Fig. 4) [76]. Differential effects ofleptin on
neurons expressing either NPY or POMC have been reported [77]. Each of
these molecules is expressed in the hypothalamus and in most instances
other brain regions as well. What follows is a briefdescription ofthe func
tional properties ofthese and other neuropeptides and neurotransmitters
that have been suggested as being components ofthe neural circuit that reg, ulates food intake and/or body weight.
W hen administered intrathecally, NPY is the most potent orexigenic
agent that is known. NPY RNA is increased in ob/ob mice and its levels
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TABLE I. HYPOTHALAMIC MODULATORS OF Fooo INTAKE
Increase food intake

Decrease food intake

NPY
AGRP
MCH
Galanin
Orexin a and b
Peptide YY
Ghrelin
Moradrenaline (a2 receptor)

a-MSH
CART
CCK
CRH
Insulin
GLP-1
Bombesin
Urocortin 1
Urocortin 2
Serotonin

decrease after leptin tt:eatment [23]. An NPY knockout attenuates the
obesity and other features of ob/ob mice indicating that it plays a role in
the response to absent leptin. Data from other knockout mice indicate
that both the Y2 and possibly Y5 receptors play a role in mediating some
of NPY's effects on food intake and body weight [78-80].
aMSH as well as MSH agonists decrease food intake. Reduced signaling
of MSH in genetically obese Nor MC-4R knockout mice results in obe
sity and leptin resistance [19, 81, 82]. Leptin modulates POMC gene ex
pression (POMC is the precursor of MSH) [83]. In addition, a subset of
neurons express both Ob-R and POMC [84]. ART, an endogenous antag
onist of melancortin signaling, is also implicated in the regulation of weight
as transgenic mice overexpressing AGRP are markedly obese [85]. In addi
tion, mRNA.for this hypothalamic peptide is increased eightfold in ob/ob
mice [86]. In aggregate, these results suggest that NPY may play a role in
mediating the response to starvation, whereas melanocortin functions in
the pathways that prevent obesity [23]. It is important to note, however,
that these molecules are likely to respond to other signals and that these
complex neural circuits are likely to interact with one another.
MCH, a neuropeptide expressed in the lateral hypothalamus, is in
creased in ob/ob mice and injections of it increase food intake in mice [87].
Mice with mutations of MCH are hypophagic and lean, thus confirming
a role for this peptide in the maintenance of body weight [88]. MCH-
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A Model of Hypothalamic Circutry of Feeding Regulation
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5-HT
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Leptin
Fig. 4. The neural circuit activated by leptin. In the arcuate nucleus of the hypothal
amus, the leptin receptor is expressed in at least two different classes of neurons. One class
expresses NYP and AGRP, two neuropeptides that increase food intake. Another class ex
presses POMC, the precursor ofaMSH and CART. Both CART and aMSH decrease food
intake. The evidence suggests that leptin suppresses the activity ofNPY/AGRP neurons and
stimulates the activity of POMC/CART neurons. Thus, in the absence of leptin the
NPY/AGRP neurons are maximally active and food intake is stimulated. In the presence of
increased leptin levels, the POMC/CART neurons are maximally active and food intake is
reduced. When an individual is at their stable weight the activity of these pathways is bal
anced. The neural mechanisms by which these neurons change food intake is not known.
Figure credit: Lex von der Plueg, Merck Pharmaceuticals.

expressing neurons receive inputs from NPY neurons in the arcuate nu
cleus and appear to relay NPY's orexigenic signal. MCH and MSH posi
tive neurons in turn project to many of the same brain regions as aMSH
and these molecules have opposite effects in food intake. Both act via dis
tinct receptors and MSH increases whereas MCH decreases cAMP sig
naling. Thus the plasma leptin concentration influences the relative
activity of anorexigenic and orexigenic circuits.
Many other neurotransmitters and neuropeptides are likely to function
in this homeostatic system (Table I) [IO]. These molecules respond to a
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number of nutritional signals, and it is likely that leptin, glucose levels,
and other signals potentiate the action of some of these anorexogenic
agents and antagonizes the orexigenic (i.e., stimulates food intake) of
others. Indeed, many leptin receptor-expressing neurons also express one
or more of these mediators (84]. T hese are briefly reviewed here.
Cholecystokinin (CCK) was the first neuropeptide suggested to play a
role in regulating food intake (89]. Injections of CCK increase satiety in
food deprived rats via afferent vagal nerves (90]. Recently, CCK was re
ported to potentiate the anorectic effect of leptin (91].
CART, a hypothalamic peptide, is also implicated as playing a role in
the response to leptin [92]. CART decreases food intake, its antibodies in
crease food intake, and its mRNA is increased in ob/ob mice. In addition,
CART co-localized with aMSH in some hypothalamic neurons.
Bombesin also reduces food intake and induced mutations of the
bombesin 3 receptor result in mild obesity (93]. A growing body of evidence
indicates that insulin acts on the hypothalamus to decrease food intake [94].
Two recently identified neuropeptides, orexin-a and orexin-b, also regulate
the state of an animal's arousal but may also modulate food intake [95, 96].
Corticotropin-releasing factor (CRF) is another factor that is likely to
mediate some of leptin's effects. CRF is expressed at high levels in the
PVN and in the amygdala, which projects to the LH [97, 98]. Addition
ally, the DMH has CRF-containing neurons (99]. CRF regulates pituitary
adrenocorhicotropic hormone (ACT H) release and adrenal glucocorticoid
secretion. Delivery of CRF to the PVN also results in reduced food intake
and increased energy expenditure in lean and obese rodents [100, 101].
Leptin has been shown to increase CRH mRNA in the PVN and to stim
ulate release of CRF from perfusion slices of both amygdala and the PVN
[102, 103]. Leptin may also inhibit the increase in CRH evident during a
stress response [104].
Glucocorticoids have long been known to play a role in regulating body
weight. Increased fat deposition is a feature of Cushings syndrome, and in
creased glucorticoids result in obesity in mice [105]. High levels of gluco
corticoids are also observed in most strains of genetically obese mice.
Moreover, adrenalectomy and glucocorticoid antagonists blunt the obesity
evident in ob/ob, db/db, and other obese mice [106, 107]. Low-dose glu
corticoid replacement restores the obese phenotype of adrenalectomized
ob/ob mice, indicating that they play a permissive role in the development
of the obese phenotype [107]. It is unclear whether the requirement for
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glucocorticoids in the development of the full ob/ob phenotype depends
on the suppression of CRH, a known effect of glucocorticoids, or if an
other mechanism is operative.
The functional relationship of these orexigenic and anorexigenic agents
is likely to have therapeutic implications. Antagonists of NPY and its re
ceptors are currently under development as are agonists of the MC4 re
ceptor [108]. Serotonin, which reduces food intake, and norepinephrine,
which is orexigenic, are both targets for known weight-reducing agents
such as fen-fen (dexfenfluramine and phentermine). A knockout of the
HT2c form of the serotonin receptor leads to a form of mild obesity [109].
Future opportunities for the development of antiobesity agents may de
pend on progress toward understanding the functional relationship among
these and other components of this neural circuit that regulates weight.
VIL EFFERENT PATHWAYS REGULATING METABOLISM
The evidence indicating that leptin can act centrally to modulate body
weight raises the following question: How does the CNS regulate periph
eral metabolism in response to differences in leptin concentration?
Whereas increasing leptin levels lead to fatty acid oxidation and a reduc
tion in adipose tissue mass, leptin deficiency, evident in ob/ob mice or mice
receiving a leptin anatgonist, is associated with an increase in fat deposi
tion [3, 11O]. In ob/ob mice, the rate of lipogenesis is markedly increased
as is the abundance of the RNAs encoding the enzymes that are rate lim
iting in fatty acid synthesis [3, 111]. It as yet unclear whether the meta
bolic derangements of ob mice are solely the result of increased food intake
or if other factors are also important.
The mechanism by which centrally administered leptin leads to lipo
lysis and the loss of adipose tissue mass is similarly unclear. The available
evidence suggests that the metabolic response to leptin is markedly dif
ferent from the response to reduced food intake. Whereas food restriction
(i.e., dieting) leads to the loss of both lean body mass and adipose tissue
mass, leptin-induced weight loss is specific for the adipose tissue mass [14,
19, 20]. Leptin also prevents the reduced energy expenditure normally as
sociated with a decreased food intake [19]. Finally, hyperleptinemic ani
mals undergoing a rapid period of weight loss fail to show any rise in
serum-ftee fatty acids or ketones [112]. This is in contrast to food
restricted (pair-fed) animals, which show a marked rise in serum-free fatty
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acids. Indeed, despite the fact that the respiratory quotient falls after leptin
treatment (indicative of fatty acid oxidation), the metabolic fate of stored
triglycerides in adipose tissue is unknown [19].
Leptin also has novel effects on glucose metabolism. The possibility that
leptin modulates glucose metabolism was first suggested in studies of ob/ob
mice treated with leptin. ob/ob mice are diabetic, and the severity of the di
abetes is dependent on the background strain carrying the mutation [3]. In
one study, leptin normalized the hyperglycemia and hyperinsulinemia evi
dent in C57BL/6J ob/ob mice at doses that did not decrease weight [21].
Antidiabetic effects have also been observed in insulin-deficient rats [113].
Leptin also corrects the insulin resistance and hyperglycemia evident in a
lipodystrophic transgenic mouse line [114]. These data confirm that leptin
has novel and clinically relevant effects on glucose metabolism.
The mechanisms by which the CNS regulates fat and glucose metabo
lism in response to leptin are also unknown. Given the dense concentra
tion of leptin receptor in the hypothalamus, there are two general
possibilities. One is that a releasing hormone is secreted into the hy
pophyseal portal system and acts to stimulate secretion of a pituitary hor
mone (known or unknown). Alternatively, leptin may activate a neural
effector pathway(s) that modulates fat and glucose metabolism. The
former seems unlikely as hypophysectomized and adrenalectomized rats
still lose copious amounts of weight after administration of centrally
infused leptin [33; unpublished data]. Furthermore, corticosterone and
thyroid hormone levels do not change in hyperleptinemic animals (un
published data). Direct measurement of nerve activity has indicated that
infusion of leptin increases sympathetic activity to brown adipose tissue,
kidney, hind limb, and adrenal gland [115, 116]. It is not yet known
whether blockade of beta adrenergic receptors attenuates (or blocks)
leptin-induced weight loss. Thus, although ICY leptin seems to modulate
the activity of the SNS, the role of the SNS in mediating the weight re
ducing effect of leptin is not established.
VIII. PATHOGENESIS OF OBESITY

In principle, alterations in body weight could be the result of abnormal
ities in the generation of the aforementioned afferent signals, the cells that
receive the signal or the efferent pathways that effect changes in weight.
Thus, the pathogenesis of obesity can be inferred in a general way by mea-
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surement of the plasma leptin levels (Fig. 5). An increase in plasma levels
suggests that obesity is the result of leptin resistance. A low or normal
plasma concentration of leptin in the context of obesity suggests decreased
production of leptin. This interpretation is similar to that relating insulin
to the pathogenesis of diabetes. However, this designation is quite general,
as a great number of hormones as well as genetic, environmental, and even
psychologic factors influence leptin sensitivity and production.
Plasma leptin levels have been measured in rodents and humans using
both radio-immunoassay (RIA) and enzyme-linked immunoassay
(ELISA) [16, 18]. In all forms of rodent obesity studied, the obese animals
have higher leptin levels than controls (not including obiob mice) [16, 17].
The data suggest that these forms of animal obesity are associated with
leptin resistance. In each of three cases that have been tested, obese ani
mals that are hyperleptinemic are indeed resistant to exogenous leptin
(complete or partial), suggesting that their obesity is the result of leptin re
sistance [19]. Diet-induced obese (D10) mice are only partially leptin re
sistant and lose moderate amounts of weight at high doses. AY mice are
completely resistant to high ICY doses of leptin and thus appear to have
a defect in the neural circuit that is activated by leptin. Indeed, the insen
sitivity of N mice to leptin strongly suggests that normal function of the
MC-4 receptor is required for the response to exogenous leptin. NZO
mice are resistant to peripherally administrated leptin but respond nor
mally to centrally administered leptin. Thus, in NZO (and possibly D10)
mice, leptin resistance may be the result of decreased transport of leptin
into the brain [19, 117]. This raises the possibility that differences in the
access of leptin to the brain could be important in the pathogenesis of
some forms of obesity. Consistent with this possibility, the levels of CSF
leptin in obese humans seems to plateau at high plasma leptin concentra
tions [118, 119].
Mutant fat and tubby mice are also hyperleptinemic [16]. The basis for
the apparent leptin resistance in these mice is unclear. Carboxypeptidase E
(CPE), the gene product of the fat locus, alters post-translational pro
cessing of many peptides including insulin, neurotensin, POMC, and
MCH [120, 121]. The identity of the substrates of CPE that regulate
weight and lead to obesity when these enzymes are defective is not known.
The tub gene product is expressed at high levels in the PVN of the hypo
thalamus [122, 123]. As mentioned, neurons in the arcuate nucleus, LH,
andNMH (sites of Ob-Rb expression), are known to project to the PVN
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Fig. 5. Pathogenesis of obesity. There are three general ways in which alterations of the
leptin regulatory loop could lead to obesity. (a) Failure to produce leptin, as occurs in ob/ob
mice, would result in obesity, as would (b) inappropriately low leptin secretion for a given
fat mass. In the latter case, the fat mass would expand until "normal" leptin levels are
reached, resulting in obesity (also see Fig. ?). (c) Finally, obesity could result from relative or
absolute insensitivity to leptin at its site of action. Such resistance would be associated with
increased circulating leptin, analogous to the increased insulin levels seen with insulin
resistant diabetes. In general, high plasma leptin levels are evident in obese rodents and hu
mans. In a subset of cases, obesity is associated with normal levels of leptin. Differences in
leptin production and leptin sensitivity could be the result of genetic, environmental and
psychological factors.

(75]. Further studies may reveal the link between this gene product and
the leptin response.
The leptin resistance observed in D10 mice emphasizes the fact that
environmental factors can modulate leptin sensitivity (19, 117]. Akr mice
(and some other strains) remain lean when fed a standard chow diet but
become obese when fed a high-fat diet. However, other mouse strains do
not become obese when exposed to an identical diet. This indicates that
the pathogenesis of diet-induced obesity is the result of an interaction be
tween genetic and environmental factors. A fuller understanding of the
mechanisms by which fat content in the diet modulates weight is likely to
be relevant to human obesity as the incidenct of obesity increases in many
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populations in proportion when exposed to a high-fat, "Western" diet
[124]. How might genes interact with environmental factors to cause obe
sity? As travelers to France well know, exposure to a highly palatable diet
often leads to transient weight gain. In most cases, the gained weight is
rapidly lost. However, it is possible that in some cases, the induced in
crease in endogenous leptin level (which accompanies weight gain) leads
to a down-regulation of the leptin response and a failure to return to the
starting weight. If tachyphylaxis to increased leptin is influenced by ge
netic factors, one might predict that a subset of individuals (and some
populations) would be especially susceptible to diet-induced obesity. The
observation that animals that express constitutive levels of leptin are in
sensitive to a high-fat diet supports this possibility. However, alternative
explanations are possible and additional studies are required. Studies to
identify the AKR alleles that predispose to diet-induced obesity may illu
minate the underlying mechanism [125, 126].
IX.

LEPTIN AND HUMAN OBESITY

In human subjects, a highly significant correlation between body fat
content and plasma leptin concentration has been observed, and obese hu
mans generally have high leptin levels [16, 18]. These data suggest that, in
most cases, human obesity is likely to be associated with insensitivity to
leptin. However, 5-10% of obese human subjects have relatively low levels
of leptin [16, 18]. Low leptin levels also predispose to weight gain in pre
obese Pima Indians [127]. These data suggest that, in some instances, obe
sity results from a subnormal secretion rate of leptin from fat.
The basis for leptin resistance in the overwhelming majority of obese,
hyperleptinemic human subjects is unknown. Data from studies of ani
mals clearly indicate that this condition is likely to be very heterogeneous
and that many factors are likely to influence the activity of the neural cir
cuit that regulates feeding behavior and body weight and/or leptin trans
port into the CNS. It has been suggested that entry of leptin into the CSF
may be limiting in some obese subjects [118, 119]. If true, the develop
ment of morbid obesity later in life could result when the plasma leptin
levels exceed the capacity of the transport system. Treatment with recom
binant leptin leads to an increase in CSF leptin concentrations in humans
[128]. Leptin uptake has been demonstrated in the capillary endothelium
of mouse and human brain and is decreased in preobese animals [69, 129,
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130]. It has thus been proposed that transport across the brain capillary
endothelium is required for leptin to find its way to its site of action in the
brain interstitial space and that Ob-Ra and/or other proteins mediate
leptin transport [69]. Moreover, defects anywhere in this transport
pathway could lead to the development of obesity.
Leptin resistance in humans is likely to be the result of a complex inter
play of many factors. In principle, leptin resistance could result from al
tered activity of any of the aforementioned components of the leptin
signal transduction pathway. Factors that directly modulate energy expen
diture or activate adipogenesis and lipogenesis could also result in ap
parent leptin resistance. Finally, leptin's actions are likely to be influenced
by psychological factors via connections between the higher cortical cen
ters that modulate an animals motivational state and neural circuits within
the hypothalamus. The neuroanatomic and functional relationships be
tween these brain regions are not well understood.
X. MUTATIONS ASSOCIATED WITH HUMAN OBESITY

In almost all cases, obese subjects express at least some leptin, an obser
vation that suggested that human ob gene mutations are likely to be rare.
Recently, two cousins born from an extended family have been found to
be homozygous for a frameshift mutation in the leptin gene. These indi
viduals do not have any circulating leptin [ 131]. In these two subjects, the
mutation is associated with profound obesity, suggesting that leptin is of
critical importance for the control of body weight in humans. Affected
members of a Turkish kindred with a missense mutation in the leptin gene
also manifest extreme obesity and amenorrhea, which further suggests that
leptin also plays a role in modulating reproductive function [132]. Similar
conclusions were reached in studies of three massively obese members of a
French family carrying mutations in the leptin receptor [133]. These three
studies also indicate that, apart from severe obesity and abnormalities of
reproductive function, the other abnormalities identifiable in ob and db
mice such as hypercortisolemia, cold intolerance, and severe diabetes are
not necessarily apparent. The heterozygous members of these families are
of normal weight.
The association of massive obesity with mutations in leptin and its re
., ceptor in humans confirms its importance in regulating body weight. This
assertion is supported by data from early clinical trials in humans (see

LEPTIN AND THE REGULATION OF BODYWEIGHT

127

below). However, mutations in these genes and other human genes in
cluding POMC, PC-1, and the MC4 receptor are relatively rare [10]. Thus,
the pathogenesis of most human obesity is largely unknown. It is likely that
some of the genes responsible for human obesity in the general population
will modulate either leptin secretion or leptin sensitivity. Both genetic and
physiologic studies will be required to confirm this prediction in humans.
XI. PROSPECTS FOR NEW TREATMENTS FOR HUMAN OBESITY
One important issue relevant for any treatment for obesity concerns the
therapeutic endpoint. The health risk of obesity is greatly diminished when
even modest amounts of weight (i.e., 5% of total weight) are lost [134,
135]. This is the result of a marked improvement in the diabetic, hyperten
sive, and cardiovascular status of obese subjects affected by these conditions
[134]. Dieting by itself is only rarely effective for the long-term maintenance
of weight loss, emphasizing the need for additional therapies [5]. Clearly, an
important indication for leptin treatment would be for the management of
the co-morbiditys associated with obesity. A recent prospective epidemio
logic study of more than one million individuals has confirmed that obesity
is an independent risk factor for increased mortality [136]. This finding am
plifies the need for efficacious and safe means for treating this disorder.
The possible therapeutic benefit of leptin treatment in humans is now
being tested in several clinical settings. It is has been demonstrated that
leptin therapy has potent weight-reducing effects in the two leptin
deficient individuals that have been treated thus far [137]. In addition to
reducing food intake, weight, and body fat content, the hormone also
stimulated cycling of gonadotropins in one of the prepubescent 11-year
old children receiving it. The efficacy of treatment with exogenous leptin
in these subjects confirms that leptin plays a physiologic role to regulate
weight in humans and also establishes a link between leptin signaling and
reproductive capacity [ 137].
Recent data from early clinical trials in the general population have
demonstrated that 4 weeks of leptin injections are safe and cause small but
significant weight loss in lean and obese subjects compared with placebo
(p < .02) (unpublished observation). Treatment of a subset of eight obese
subjects for a total of 6 months resulted in an average weight loss of 7.1 kg
in a group receiving 0.3 mg/kg leptin vs. 1.7 kg in a group receiving
placebo. Some of the subjects in this group lost substantial amounts of
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weight whereas others did not. This limited study suggests that leptin
could ultimately emerge as an effective therapy for some obese subjects, al
though studies of more patients are clearly required (138].
Further studies to determine the possible utility of leptin for the treat
ment of Type II diabetes are also indicated, as animal studies suggest that
leptin can increase glucose metabolism independent of weight (21, 67,
139]. It is also possible that leptin could be of therapeutic benefit for the
maintenance of weight loss after a diet (rather than as a means to induce
weight loss). In humans, diet-induced weight loss results in a decrease in
plasma leptin concentration (16]. This provides a possible explanation for
the high failure rate of dieting, as a low leptin level is likely to be a potent
stimulus for weight gain. Thus, leptin treatment after a very low calorie
diet (VLCD) could, in principle, reduce the 95% failure rate of diets for
long-term maintenance of weight loss. Further studies should reveal
whether leptin is of therapeutic value in some obese subjects.
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